1. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells.
- Author
-
Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, and Calvi LM
- Subjects
- Aging genetics, Aging pathology, Animals, Base Sequence, Bone Density drug effects, Bone Density genetics, Bone Density physiology, Bone Remodeling drug effects, Bone Remodeling genetics, Bone Remodeling physiology, Bone and Bones anatomy & histology, Bone and Bones drug effects, Bone and Bones physiology, Cadherins deficiency, Cadherins genetics, Cellular Microenvironment physiology, Hematopoiesis drug effects, Hematopoiesis genetics, Hematopoiesis physiology, Hematopoietic Stem Cells drug effects, Male, Mice, Mice, 129 Strain, Mice, Inbred C57BL, Mice, Transgenic, Osteoblasts drug effects, Parathyroid Hormone pharmacology, RNA, Messenger genetics, RNA, Messenger metabolism, Cadherins physiology, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells physiology, Osteoblasts cytology, Osteoblasts physiology
- Abstract
Hematopoietic stem cell (HSC) regulation is highly dependent on interactions with the marrow microenvironment. Controversy exists on N-cadherin's role in support of HSCs. Specifically, it is unknown whether microenvironmental N-cadherin is required for normal marrow microarchitecture and for hematopoiesis. To determine whether osteoblastic N-cadherin is required for HSC regulation, we used a genetic murine model in which deletion of Cdh2, the gene encoding N-cadherin, has been targeted to cells of the osteoblastic lineage. Targeted deletion of N-cadherin resulted in an age-dependent bone phenotype, ultimately characterized by decreased mineralized bone, but no difference in steady-state HSC numbers or function at any time tested, and normal recovery from myeloablative injury. Intermittent parathyroid hormone (PTH) treatment is well established as anabolic to bone and to increase marrow HSCs through microenvironmental interactions. Lack of osteoblastic N-cadherin did not block the bone anabolic or the HSC effects of PTH treatment. This report demonstrates that osteoblastic N-cadherin is not required for regulation of steady-state hematopoiesis, HSC response to myeloablation, or for rapid expansion of HSCs through intermittent treatment with PTH.
- Published
- 2012
- Full Text
- View/download PDF